Clinical trials: Paclitaxel, completed
Treatment Of Stenotic Lesions In Native Coronary Arteries.
BioFreedom FIM Clinical Trial.
Prospective, multi center, randomized, single blinded study designed to demonstrate the safety and effectiveness of the Biosensors BioFreedom Drug-Eluting Coronary Stent Delivery System at multiple time points compared to the…
- Trial name
- NCT01172119
- Testing
- Biofreedom Drug Eluting Stent, Tuxus Liberte Drug Eluting Stent
- Where
- 4 sites in Germany
- Volunteers
- 182 people
- Sponsor
- Biosensors Europe SA
Squamous Cell Carcinoma of the Head and Neck
Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.
Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT04672772
- Testing
- Cetuximab, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 531 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Breast Cancer
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
This multicenter study in participants with HER2-positive eBC will investigate participants' pain and discomfort of SC trastuzumab (Herceptin) administered either via a single-use injection device (SID) or via vial for manual…
- Trial name
- ESCAPE (NCT02194166)
- Testing
- Trastuzumab, Paclitaxel, Docetaxel
- Where
- 7 sites in Belarus, Kazakhstan
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Malignant Neoplasm of Breast
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
Despite its aggressiveness and high incidence, to date, no targeted therapies exist for the treatment of triple negative breast cancer (TNBC).
- Trial name
- NIB (NCT03289819)
- Testing
- Pembrolizumab, nab-paclitaxel, Epirubicin
- Where
- 4 sites in Germany
- Volunteers
- 53 people
- Sponsor
- Institut fuer Frauengesundheit
Esophageal Cancer
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant…
- Trial name
- NCT02735239
- Testing
- Durvalumab, Tremelimumab, Oxaliplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Ludwig Institute for Cancer Research
Breast Cancer, Neoplasm Metastasis
Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.
Tolerance and efficacy of administration of capecitabine 5 out of 7 days associated with weekly paclitaxel compared to the recommended treatment plan of weekly paclitaxel - capecitabine, in patients with metastatic breast cancer.
- Trial name
- NCT00270491
- Testing
- Paclitaxel, Capecitabine
- Where
- France
- Volunteers
- 130 people
- Sponsor
- ARCAGY/ GINECO GROUP
Solid Tumor, Ovarian Cancer
LDE225 and Paclitaxel in Solid Tumors
The primary aim of this trial is to establish the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of LDE225 given in combination with standard doses of paclitaxel in patients with advanced solid tumors.
- Trial name
- NCT01954355
- Testing
- LDE225, Paclitaxel
- Where
- 4 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer
The primary objective of this study is to compare disease-free survival (DFS) of patients with operable breast cancer randomised to treatment with standard adjuvant chemotherapy plus moxifloxacin or placebo.
- Trial name
- NCT05114720
- Testing
- standard adjuvant chemotherapy plus moxifloxacin
- Where
- China
- Volunteers
- 559 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer, Metastatic Pancreatic Cancer
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
In this study, clinical data of patients who received 2nd-line Nab-paclitaxel plus Gemcitabine (nab-P+GEM) after progression on 1st-line FOLFIRINOX will be reviewed retrospectively.
- Trial name
- NCT04133155
- Testing
- nab paclitaxel plus gemcitabine
- Where
- South Korea
- Volunteers
- 103 people
- Sponsor
- Asan Medical Center
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.
- Trial name
- NCT02754726
- Testing
- Nivolumab, Albumin-bound paclitaxel, Paricalcitol
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- HonorHealth Research Institute
Biliary Cancer Metastatic
Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial
This prospective, single-center, single-arm phase II clinical trial was designed to evaluate the efficacy and safety of bevacizumab plus nab-paclitaxel and S-1 as second-line treatment for patients with advanced biliary tract…
- Trial name
- NCT07719738
- Testing
- Bevacizumab+nab-paclitaxel+tegafur gimeracil oteracil potassium capsule (S-1)
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fallopian Tube Cancer, Ovarian Cancer
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00014690
- Testing
- plevitrexed, topotecan hydrochloride
- Where
- United States
- Sponsor
- AstraZeneca
Peritoneal Carcinomatosis, Gastric Cancer
Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer
The aims of this study are to investigate whether multimodal treatment of peritoneal carcinomatosis from gastric cancer is feasible and to evaluate the clinical outcomes and clinical effectiveness of neoadjuvant systemic…
- Trial name
- NCT01379482
- Testing
- Multimodal treatment
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Uppsala University
HER2-positive Locally Advanced or Metastatic Breast Cancer
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer…
- Trial name
- PRECIOUS (NCT02514681)
- Testing
- Trastuzumab, Pertuzumab, Docetaxel
- Where
- 3 sites in Japan
- Volunteers
- 226 people
- Sponsor
- Japan Breast Cancer Research Group
Her2-Positive Breast Cancer
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
The main goal of this clinical trial is to test if adding pertuzumab (Perjeta), improves the anticancer activity of the combination chemotherapy regimen of trastuzumab (Herceptin) concomitant with paclitaxel, 5-fluorouracil…
- Trial name
- NCT01855828
- Testing
- Pertuzumab, Trastuzumab, Paclitaxel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
Adenocarcinoma, Bronchiolo-Alveolar
Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma
To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.
- Trial name
- NCT00384826
- Testing
- erlotinib, paclitaxel + carboplatine
- Where
- 9 sites in France
- Volunteers
- 133 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Femoral Artery Stenosis, Popliteal Artery Stenosis
MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery
The purpose of this trial is to assess the safety and efficacy of MDT-2113 for the interventional treatment of de novo and non-stented restenotic lesions in the superficial femoral artery (SFA) and the proximal popliteal artery…
- Conditions
- Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
- Trial name
- MDT-2113 SFA (NCT01947478)
- Testing
- MDT-2113 Drug-Eluting Balloon, Standard angioplasty balloon
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Medtronic Endovascular
Ovarian Cancer
Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
The purpose of this study is to evaluate the safety and activity of adding pazopanib to weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or refractory to treatment with platinum based therapy.
- Trial name
- MITO-11 (NCT01644825)
- Testing
- paclitaxel, pazopanib
- Where
- 20 sites in Italy
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute, Naples
Urologic Neoplasm
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.
- Trial name
- NCT00350025
- Testing
- Cetuximab, Paclitaxel
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Fox Chase Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.